The Polypill Approach for Multiple Cardiovascular Risk Factors (PACIF) trial is a multicenter randomized controlled trial that will test the effectiveness and safety of a fixed-dose combination strategy for the integrated management of hypertension, dyslipidemia, and type 2 diabetes among adults aged 50 to 75 years without prior cardiovascular disease in China. The trial will evaluate whether a fixed-dose combination strategy improves the 10-year cardiovascular disease risk estimated using the PREVENT equations at Phase 1. Participants will be further followed to determine whether the fixed-dose combination strategy reduces major cardiovascular events and improves cognitive outcomes compared with usual care at Phase 2.
The overall objective of the PACIF Trial is to test a fixed-dose combination strategy for the integrated management of hypertension, dyslipidemia, and diabetes. This multicenter randomized controlled trial will evaluate whether a polypill-based approach, compared with usual care, improves cardiovascular risk factor control and reduces cardiovascular disease events among adults with multiple cardiovascular risk factors but without prior cardiovascular disease. The trial will recruit an estimated 8,252 participants aged 50 to \<75 years who have hypertension, dyslipidemia, and type 2 diabetes. Participants will be randomly assigned to receive either a fixed-dose combination strategy or usual care. In the intervention group, the study medication regimen will consist of eight prespecified fixed-dose formulations combining blood pressure-lowering, lipid-lowering, and glucose-lowering therapies. These formulations include olmesartan medoxomil/amlodipine, rosuvastatin, ezetimibe, and dapagliflozin, with indapamide included in selected formulations. Treatment will be adjusted among the prespecified fixed-dose formulations according to participants' blood pressure levels, treatment targets, tolerability, and safety. Additional open-label medications may be used according to guideline recommendations and clinical judgment if the prespecified treatment targets are not achieved with the fixed-dose combination strategy. Treatment targets are defined as blood pressure \<130/80 mmHg, LDL cholesterol \<1.8 mmol/L, and HbA1c \<7.0%. The primary outcome at Phase 1 is the ACC/AHA 10-year cardiovascular disease risk estimated by the PREVENT equations. In addition, changes in PREVENT-estimated 10-year ASCVD and heart failure risk, the proportions of participants achieving the prespecified blood pressure, lipid, and glycemic targets, and changes in individual cardiovascular risk factors will also be evaluated. The primary outcome at Phase 2 is a composite cardiovascular disease outcome including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, heart failure requiring hospitalization or treatment, and coronary revascularization. Cognitive outcomes will also be assessed, with incident all-cause dementia prespecified as a major secondary outcome.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
8,252
Participants assigned to the intervention group will receive a fixed-dose combination strategy for the integrated control of blood pressure, lipid, and glucose. Eight prespecified fixed-dose formulations will be used, differing in antihypertensive intensity and rosuvastatin dose. All formulations will include olmesartan medoxomil/amlodipine, rosuvastatin, ezetimibe 10 mg, and dapagliflozin 10 mg, with indapamide 2.5 mg included in selected formulations. The olmesartan medoxomil/amlodipine dose will range from 5/1.25 mg to 20/5 mg, and the rosuvastatin dose will be either 5 mg or 10 mg. Treatment will be selected and adjusted among the prespecified fixed-dose formulations according to participants' blood pressure levels, treatment targets, tolerability, and safety. If the prespecified blood pressure, lipid, or glycemic targets are not achieved despite the highest fixed-dose regimen, additional open-label medications may be prescribed according to guideline recommendations.
The First Affiliated Hospital of Henan University of Chinese Medicine
Zhengzhou, Henan, China
NOT_YET_RECRUITINGAffiliated Hospital of Chifeng University
Chifeng, Inner Mongolia, China
RECRUITINGTongliao People's Hospital
Tongliao, Inner Mongolia, China
NOT_YET_RECRUITINGKunshan Hospital of Chinese Medicine
Kunshan, Jiangsu, China
NOT_YET_RECRUITINGSuzhou Wujiang District Hospital of Traditional Chinese Medicine
Suzhou, Jiangsu, China
NOT_YET_RECRUITINGThe Fifth People's Hospital of Wujiang District
Suzhou, Jiangsu, China
NOT_YET_RECRUITINGThe Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
NOT_YET_RECRUITINGTaixing Second People's Hospital
Taizhou, Jiangsu, China
NOT_YET_RECRUITINGCentral Hospital of Jinzhou
Jinzhou, Liaoning, China
RECRUITINGPanjin Central Hospital
Panjin, Liaoning, China
NOT_YET_RECRUITING...and 5 more locations
10-year CVD risk
Changes in 10-year CVD risk estimated by the PREVENT equations
Time frame: 12 months
Composite cardiovascular disease outcome
Record the occurrence of the composite cardiovascular disease outcome, including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, heart failure requiring hospitalization or treatment, and coronary revascularization
Time frame: 36 months
Major secondary endpoint: All-cause dementia
Record the occurrence of all-cause dementia
Time frame: 36 months
Hierarchical composite of all-cause mortality, nonfatal cardiovascular events, and improvement in 10-year cardiovascular disease risk estimated by the PREVENT equations
Hierarchical composite of all-cause mortality, nonfatal cardiovascular events, and improvement in 10-year cardiovascular disease risk estimated by the PREVENT equations
Time frame: 12 months
10-year ASCVD risk
Changes in 10-year ASCVD risk estimated by the PREVENT equations
Time frame: 12 months
10-year HF risk
Changes in 10-year HF risk estimated by the PREVENT equations
Time frame: 12 months
The proportions of participants achieving the prespecified blood pressure, LDL-C, and HbA1c targets, individually and jointly
The proportions of participants achieving the prespecified targets for blood pressure (systolic blood pressure \<130 mmHg and diastolic blood pressure \<80 mmHg), LDL-C (\<1.8 mmol/L), and HbA1c (\<7.0%), individually and jointly
Time frame: 12 months
Blood pressure, LDL-C, and HbA1c
Changes in systolic and diastolic blood pressure, LDL-C, and HbA1c
Time frame: 12 months
Medication adherence
Medication adherence assessed by participant self-report, pill count, or other prespecified adherence measures
Time frame: 12 months
Cost-effectiveness
Data on the costs of CVD risk assessment and management will be collected for both study groups. The cost-effectiveness analysis will estimate the incremental cost per unit reduction in estimated 10-year CVD risk in the intervention group compared with the control group.
Time frame: 12 months
Hierarchical composite of all-cause mortality, nonfatal cardiovascular events, and improvement in 10-year cardiovascular disease risk estimated by the PREVENT equations
Hierarchical composite of all-cause mortality, nonfatal cardiovascular events, and improvement in 10-year cardiovascular disease risk estimated by the PREVENT equations
Time frame: 36 months
The proportions of participants achieving the prespecified blood pressure, LDL-C, and HbA1c targets, individually and jointly
The proportions of participants achieving the prespecified targets for blood pressure (systolic blood pressure \<130 mmHg and diastolic blood pressure \<80 mmHg), LDL-C (\<1.8 mmol/L), and HbA1c (\<7.0%), individually and jointly
Time frame: 36 months
Blood pressure, LDL-C, and HbA1c
Changes in systolic and diastolic blood pressure, LDL-C, and HbA1c
Time frame: 36 months
Composite outcome of composite cardiovascular disease outcome or deaths
Record the occurrence of composite outcome of composite cardiovascular disease outcome or deaths
Time frame: 36 months
Macrovascular outcome
Record the occurrence of any of the following: stroke, myocardial infarction, heart failure requiring hospitalization or treatment, aortic dissection, any cardiovascular revascularization procedures, or cardiovascular death
Time frame: 36 months
Major coronary artery diseases
Record the occurrence of any of the following: myocardial infarction, revascularization of coronary arteries, or deaths due to coronary artery diseases
Time frame: 36 months
Myocardial infarction
Record the occurrence of myocardial infarction
Time frame: 36 months
Stroke
Record the occurrence of stroke
Time frame: 36 months
Ischemic stroke
Record the occurrence of ischemic stroke
Time frame: 36 months
Hemorrhagic stoke
Record the occurrence of hemorrhagic stroke
Time frame: 36 months
Heart failure requiring hospitalization or treatment
Record the occurrence of heart failure requiring hospitalization or treatment
Time frame: 36 months
Coronary revascularization
Record the occurrence of coronary revascularization
Time frame: 36 months
Cardiovascular disease death
Record the occurrence of cardiovascular disease death
Time frame: 36 months
All-cause death
Record the occurrence of all-cause death
Time frame: 36 months
Microvascular outcomes
Record the occurrence of microvascular complications (e.g., diabetic kidney disease and diabetic peripheral neuropathy)
Time frame: 36 months
New-onset chronic kidney disease or progression of chronic kidney disease
Record the occurrence of new-onset chronic kidney disease or progression of chronic kidney disease
Time frame: 36 months
Mild cognitive impairment
Record the occurrence of mild cognitive impairment
Time frame: 36 months
Composite outcome of dementia and mild cognitive impairment
Record the occurrence of the composite outcome of dementia and mild cognitive impairment
Time frame: 36 months
Composite outcome of dementia and all-cause death
Record the occurrence of the composite outcome of dementia and all-cause death
Time frame: 36 months
Medication adherence
Medication adherence assessed by participant self-report, pill count, or other prespecified adherence measures
Time frame: 36 months
Health related quality of life
Health-related quality of life will be assessed by the Five-Level Version of the EQ-5D (EQ-5D-5L). In this questionnaire, 5 dimensions are measured in 5 items: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. A 5-point Likert scale ranging from "no problems" to "extreme problems" is used for every dimension, with higher scores reflecting more problems in a dimension. A VAS ranging from 0 to 100 (0 = "The best health you can imagine" to 100 = "The worst health you can imagine") is applied as well, with higher scores indicating a better health state as perceived by the patient.
Time frame: 36 months
Cost-effectiveness
Cost-effectiveness assessed by the incremental cost-effectiveness ratio, expressed as the incremental cost per quality-adjusted life-year gained. Quality-adjusted life-years will be estimated from health utilities derived using the EQ-5D-5L questionnaire.
Time frame: 36 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.